Radhika Armandla is a Senior Research Specialist in the Powers & Brissova Research Group at Vanderbilt University. She is involved in projects dealing with human islet transplantation, in vitro analysis and imaging in order to study human islet survival, function, regeneration and proliferation.
Anil Bhushan is a Professor at the University of California, San Francisco. His research goal is to understand the role of tissue secretory senescent cells in aging, autoimmunity and metabolic diseases. One of his recent discoveries shows that pancreatic beta cells acquire a secretome during T1D in mice and human and exhibit many non-cell autonomous properties.
Olivier Blondel is a NIH NIDDK Program Director in the Division of Diabetes, Endocrinology, and Metabolic Diseases. His interests lie in research that focuses on endocrine signaling, stem cell biology, organ development, regenerative medicine and biomarker discovery as it relates to diabetes (type 1 and type 2) and metabolic diseases, particularly in combination with experimental approaches such as large-scale genomics, synthetic biology, bioengineering, epigenetics, nuclear organization of mammalian genomes, chromatin biology, genome editing, gene therapy
Marcela Brissova is an Research Professor of Medicine and Director of the Islet Procurement & Analysis Core at Vanderbilt University. She is also the Director of the Human Islet Phenotyping Program (HIPP) of IIDP. Her research focuses on the biology of pancreatic islets and pancreas and islet development, especially the development of pancreatic islet vasculature and innervation and their role in regulation of pancreatic islet function.
Peter Buchwald is an Associate Professor in the Department of Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine and the Director of the Drug Discovery Program at the Diabetes Research Institute. He has published numerous articles in peer-reviewed journals focused on the physicochemical and metabolic aspects of drug design and drug action, as well as on computer-aided quantitative modeling. Dr. Buchwald is directing the DRI’s efforts aimed at developing safer and more effective drugs for islet replacement therapies.
Chunhua Dai is a Research Associate Professor in the Powers & Brissova Research Group at Vanderbilt University. Her research focuses on the molecular, cellular, and vascular changes in human islets when they are challenged with hyperglycemia and/or insulin resistance in vivo. She is investigating in vivo age-dependent human beta cell proliferation and how current therapeutic agents for type 2 diabetes preserve and/or enhance human beta cell function or survival in vivo.
Sangeeta Dhawan is a HIRN New Investigator and an Assistant Professor in the Department of Translational Research & Cellular Therapeutics. Her research focuses on the understanding the biology of the insulin producing beta cells.
Yuval Dor is a Professor of Biology at the Hebrew University of Jerusalem. He has worked in the past mostly on diabetes and tissue regeneration in the pancreas, but in recent years much of our focus has shifted to a new technology that we are developing, for non-invasive monitoring of cell death in humans, based on circulating DNA.
Abdelfattah El Ouaamari is a HIRN New Investigator and an Assistant Professor in Medicine at Robert Wood Johnson Medical School at Rutgers University. His research employs a multidisciplinary approach to identify local, systemic and neuronal signals regulating the number and the function of pancreatic islet insulin-producing β cells in mouse and human models of obesity and diabetes.
Markus Grompe is Professor and Director Family Pediatric Research Institute at Oregon Health & Science University in Portland, Oregon. His research focuses on the use of in vivo selection to enhance gene and cell transplantation therapy for inherited diseases.
Klaus Kaestner Professor in Genetics at the Perelman School of Medicine at the University of Pennsylvania and the Director of the Functional Genomics Core at the University of Pennsylvania. His research interest is in employing modern genetic, genomic and epigenomic approaches (ChIP-Seq, RNA-Seq, gene targeting, tissue-specific and inducible gene ablation, CyTOF) to understand the molecular mechanisms of organogenesis and physiology of the liver, pancreas and gastrointestinal tract. Disease areas targeted by our research include diabetes and cancer.
Mark Kay is a Professor of Pediatrics and Genetics at Stanford University. His laboratory is focused in the development of gene transfer vectors for gene therapy as well as manipulating non-coding RNAs for therapeutic purposes. His research has focused on two vector systems, mini-circles and recombinant AAVs (rAAV). Using gene transfer vectors, we studied the potential of using transcriptional-based RNAi to treat human disease.
Seung Kim is a Professor of Developmental Biology and Medicine (Oncology) at Stanford University School of Medicine. His research focuses on the developmental biology of the pancreas, a vital organ with endocrine and exocrine functions in the vertebrate digestive tract. One goal of our work is to translate our studies into novel diagnostic and therapeutic strategies for common pancreatic disease states in humans, particularly diabetes mellitus and pancreatic cancer.
Rohit Kulkarni is a Professor of Medicine at Harvard Medical School and Co-Head of the Section on Islet & Regenerative Biology at Joslin Diabetes Center. His research explores the significance of growth factor signaling mechanisms in the regulation of islet biology by creating genetic models to examine the roles of insulin/IGF-1 receptors and their substrate proteins.
Heiko Lickert is a Professor and Chair of Beta Cell Biology in the Medical Faculty of the Technical University Munich, the Director of the Institute of Diabetes and Regeneration Research and Principal Investigator in the Institute of Stem Cell Research at the Helmholtz Center Munich.
Everett Meyer is an Assciate Professor of Medicine at Stanford University Medical School. His research focus is in hematopoietic stem cell transplantation and Treg cell immunotherapy, with an emphasis on the treatment of graft-versus-host disease as well as immune tolerance induction for transplantation and autoimmunity. He is an expert on the role of T-cell populations in immune dysregulation, specifically through the mechanistic study of how CD1d-restricted invariant NKT mediate allergy and asthma in both mouse models and human clinical samples.
Hiroyuki Nakai is a Professor of Molecular and Medical Genetics at the Oregon Health and Science University School of Medicine. His research goals are to comprehensively understand the biology of recombinant AAV vectors and the vector-host interactions and to develop new AAV vector-mediated gene and cell therapies to treat various human diseases.
Feroz Papa is a Professor in the Department of Medicine at the University of California, San Francisco Biomedical Sciences Graduate Program. His lab uses molecular, cellular, and organismal approaches to address broad questions revolving around protein misfolding and disease. His research focuses in protein misfolding in the endoplasmic reticulum (ER) organelle.
Vincent Poitout is a Professor in the Department of Medicine at the University of Montreal. His research focuses on the regulation of pancreatic beta-cell function and its dysregulation in type 2 diabetes. He is exploring the role of nutrient-sensing G Protein-Coupled Receptors (GPCRs) and Regulators of G protein Signaling (RGS proteins) in pancreatic islet function and glucose homeostasis.
Al Powers is a Professor of Medicine, Molecular Physiology and Biophysics at Vanderbilt University. He is also the Director of the Vanderbilt Diabetes Center, Director of the Vanderbilt Diabetes Research and Training Center, and Chief of the Vanderbilt Division of Diabetes, Endocrinology, and Metabolism. His research focuses on pancreatic islet biology, vascularization, development, regeneration, and imaging.
Guy Rutter is a Professor of Cell Biology and Functional Genomics at Imperial College of London. His research focuses on signal transduction in the pancreatic β-cell in health and disease - my chief focus is in using functional genomics at the cellular and whole organism level to dissect the role of genes associated with Type 2 diabetes.
Bridget Wagner is the chair of the Consortium of Targeting and Regeneration (CTAR) and the Trans-Network Committee (TNC). Additionlly, she is a CTAR Investigator. She is also the Director of Pancreatic Cell Biology and Metabolic Disease in the Chemical Biology and Therapeutic Sciences Program at the Broad Institute of MIT and Harvard, where she is also an institute scientist. Her research focuses on the chemical biology of diabetes, with the aim of identifying small molecules capable of increasing pancreatic beta cell number and function and the ultimate goal of discovering new therapeutic approaches for diabetes.
Xujing Wang is a NIH NIDDK Program Director in the Division of Diabetes, Endocrinology, and Metabolic Diseases. Her interests are in data science, computation modeling, integrative genomics, network biology, and genotype-phenotype relationships.
Joe Zhou is a Professor of Regenerative Medicine at Weill Cornell Medicine. His research studies the pancreatic insulin-secreting beta-cells and the gut stem cells with the aim to developing new regenerative medicine approaches to treat diabetes, digestive failure, and inflammatory bowel diseases. By understanding how specific tissues are formed from stem cells, we apply master genes and signaling pathways to reprogram adult cells and regrow tissues in adult organs.